Georgia Bio Signs-on Multi-Association Letter on Buy American Executive Order

Today Georgia Bio joins several other associations to sign-on the U.S. Chamber Letter to Secretary Mnuchin, Secretary Ross, Ambassador Lighthizer, and Director Kudlow.

The letter respectfully ask that the Trump administration defer moves to expand the reach of “Buy American” mandates to the medical equipment and biopharmaceutical sector during the present national emergency.


Please see below to read the full letter:

The undersigned organizations applaud the Trump administration’s focused response to the coronavirus pandemic. In particular, we appreciate the administration’s encouragement of public-private partnerships to quickly develop a vaccine for COVID-19 and expand the supply of medical countermeasures. We also commend the administration’s efforts to work with tech companies to map the spread of the coronavirus as well as FDA efforts to loosen regulations and increase testing capacities. American companies will do whatever it takes to support our country’s pandemic response and will continue to work hand in glove with government to get the job done.

While we are encouraged by this partnership and the administration’s ongoing labors with our international allies to respond to the pandemic with all available resources, we are concerned by reports of a draft “Buy American” executive order that could be counterproductive to these efforts. Such an order may delay the discovery of a COVID-19 vaccine and other treatments, worsen shortages of critically-needed medicines and medical products, and undermine prospects for economic recovery.

Now more than ever, U.S. industries require access to international supply chains to produce critically-needed medical products. The United States simply does not produce all of the raw materials or intermediate goods that are essential to drug development or production of the medical equipment needed to thwart this epidemic. Preventing federal agencies from sourcing medical equipment and pharmaceutical ingredients from abroad — or that are made with non-U.S. inputs — will only exacerbate the supply shortages racking the United States.

Further, as the world’s most innovative economy, the United States cannot shut itself off from the rest of the world. Turning our backs on trading partners during a crisis could damage our relationships long after this pandemic ends. If we implement localization requirements, many of our trade partners would assuredly follow our lead and limit imports from the United States.

For these reasons, we respectfully ask that the Trump administration defer moves to expand the reach of “Buy American” mandates to the medical equipment and biopharmaceutical sector during the present national emergency. This pandemic has raised awareness of vulnerabilities in supply chains, and American industries look forward to working with the administration to solve those challenges with well-thought-out solutions, but those efforts should be deferred until the national emergency is passed.

Today, our shared priority must be to defeat COVID-19. The U.S. business community is committed to doing whatever it takes — working in close partnership with you — to achieve this goal.

May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology
April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities
April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
MORE POSTS